JUPITER NEUROSCIENCES, INC. Operating Cash Flow
JUPITER NEUROSCIENCES, INC. (JUNS) reported Operating Cash Flow of -$3.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- JUPITER NEUROSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$2.29M.
- JUPITER NEUROSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.43M.
- JUPITER NEUROSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$2.37M.
- JUPITER NEUROSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.15M.
- JUPITER NEUROSCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$5.41M.
- JUPITER NEUROSCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$3.91M.
- JUPITER NEUROSCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$480.95K.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$3.73M 10-Q · filed 2026-08-14 | -$6.10M derived: sum of 3 quarters · filed 2026-08-14 | -$7.25M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$1.43M 10-Q · filed 2026-05-14 | -$3.80M derived: sum of 2 quarters · filed 2026-05-14 | -$4.95M derived: sum of 3 quarters · filed 2026-05-14 | -$5.78M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | -$3.52M derived: sum of 2 quarters · filed 2026-04-01 | -$4.35M derived: sum of 3 quarters · filed 2026-08-14 | -$5.41M 10-K · filed 2026-04-01 |
| 2025-09-30 | -$1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$1.98M derived: sum of 2 quarters · filed 2026-08-14 | -$3.05M 10-Q · filed 2025-11-14 | -$6.74M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$828.22K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.89M 10-Q · filed 2026-08-14 | -$5.59M derived: sum of 3 quarters · filed 2026-08-14 | -$5.63M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$1.06M 10-Q · filed 2026-05-14 | -$4.76M derived: sum of 2 quarters · filed 2026-05-14 | -$4.80M derived: sum of 3 quarters · filed 2026-05-14 | -$4.91M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | -$3.74M derived: sum of 2 quarters · filed 2026-04-01 | -$3.85M derived: sum of 3 quarters · filed 2026-04-01 | -$3.91M 10-K · filed 2026-04-01 |
| 2024-09-30 | -$42.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$150.06K derived: sum of 2 quarters · filed 2025-11-14 | -$215.22K 10-Q · filed 2025-11-14 | -$376.36K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$107.46K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | -$172.63K 10-Q · filed 2025-08-19 | -$333.76K derived: sum of 3 quarters · filed 2025-08-19 | |
| 2024-03-31 | -$65.17K 10-Q · filed 2025-05-15 | -$226.30K derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | -$161.14K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$480.95K 10-K · filed 2025-03-28 | ||
| 2023-09-30 | -$319.82K 10-Q · filed 2024-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |